Objective: Adipose-derived stem cells (ASCs) are a potential adult mesenchymal stem cell source for restoring endothelial function in patients with critical limb ischemia. Fibroblast growth factor 2 (FGF2) and vascular endothelial growth factor (VEGF) play a major role in angiogenesis and wound healing. This study evaluated the effects of FGF and VEGF on the proliferation, migration, and potential endothelial differentiation of human ASCs with regards to their use as endothelial cell substitutes. Methods: ASCs were isolated from clinical lipoaspirates and cultured in M199 medium with fetal bovine serum (10%), FGF2 (10 ng/mL), VEGF (50 ng/mL), or combinations of FGF2 and VEGF. Cell proliferation rates, viability, and migration were measured by growth curves, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), and scratch assays. For cell attachment determinations, ASCs were seeded onto a scaffold of small intestinal submucosa for 5 days. Endothelial differentiation capabilities of ASCs were confirmed by expression of endothelial cell-specific markers using quantitative polymerase chain reaction, immunofluorescence staining, and cord formation on Matrigel (BD Biosciences, San Jose, Calif). PD173074, a selective inhibitor of FGF receptor, was used to confirm the importance of FGF signaling. Results: ASCs treated with FGF or combinations of FGF and VEGF showed increased proliferation rates and consistent differentiation toward an endothelial cell lineage increase in platelet endothelial cell adhesion molecule (CD31), von Willebrand factor, endothelial nitric oxide synthase, and vascular endothelial cadherin message, and in protein and cord formation on Matrigel. FGF and VEGF stimulated ASC migration and increased the attachment and retention after seeding onto a matrix graft of small intestinal submucosa. Blockade of FGF signaling with PD173074 abrogated ASC endothelial cell differentiation potential. Conclusions: These results indicate that FGF and VEGF are ASC promoters for proliferation, migration, attachment, and endothelial differentiation. FGF and VEGF have a costimulatory effect on ASC endotheliogenesis. These results further suggest that ASCs with enhanced FGF signaling may potentially be used for tissue engineering and cell-based therapies in patients with critical limb ischemia. (J Vasc Surg 2017;65:1483-92.) Clinical Relevance: Endothelial dysfunction is a primary mediator of vascular disease and critical limb ischemia. Treatment of this disease state is limited by available conduit and the inherent thrombogenicity of bypass grafts. Development of phenotypically and functionally similar endothelial cells from adipose-derived stem cells may allow for the creation of vascular conduits that are readily available and provide increased patency rates. Our study differentiated a cell line from human adipose that could be manipulated into endothelial cells that exhibit characteristics of endothelial cells, providing further information to already existing literature.
Critical limb ischemia is a clinical condition driven by endothelial dysfunction and injury. Traditional therapy for these patients has been aimed at vascular bypass grafts and endovascular stenting. Conduits for vascular bypasses include autologous vein graft or prosthetic conduit. However, autologous vein is limited, and synthetic conduits are less durable. 1 More recently, cell therapy has been developed as a potential angiogenic therapy. 2 With the advent of cell-based regenerative medicine, a new approach to the treatment of these patients may be at the forefront of future therapeutic options.
Adipose-derived stem cells (ASCs) are able to differentiate into multiple cell lineages, including endothelial, adipogenic, osteogenic, chondrogenic, and myogenic cell lines. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] This has previously been reported to be the result of a cellular milieu of various soluble factors produced by the ASCs themselves.
14 This secretory profile of ASCs is regulated by exposure to different agents. 15, 16 With the prominent role the cellular environment of ASCs plays, in vitro studies have focused on manipulating the culture medium of the ASCs in an effort to direct differentiation patterns in a lineage-specific pattern. 17, 18 Studies have shown that by treating ASCs with endothelial growth medium (EGM2), ASCs could be differentiated into endothelial-like cells. Fibroblast growth factor 2 (FGF2) and vascular endothelial growth factor (VEGF) have both been implicated in this differentiation pathway. [18] [19] [20] FGF is a growth factor involved in angiogenesis, wound healing, embryonic development, and various endocrine-signaling pathways. ASCs cultured in medium supplemented with FGF express morphologic changes of mature endothelial cells and also express endothelial markers. 4 FGF has proliferative effects in multipotent human stem cells, [21] [22] [23] [24] and more importantly, FGF controls differentiation of ASCs and is involved with endothelial cell migration. 25 VEGF is a growth factor that promotes endothelial survival, proliferation, and migration. [26] [27] [28] Research has shown that adult stem cells in culture medium supplemented with VEGF express endothelial-specific markers and that inhibition of the VEGF pathway leads to decreased messenger (m)RNA levels of these markers. 28 In the field of vascular surgery, this multipotency of ASCs that have been treated with growth factors may allow for their application in cell-based regenerative therapies. 2, 29, 30 To date, some groups have attempted seeding prosthetic graft material but have reported minimal success secondary to the thrombogenic nature of these grafts. This has been partly attributed to the inability of these stem cellseeded grafts to produce endothelial nitric oxide synthase (eNOS), a critical protein produced by endogenous endothelial cells. 31 Given the previous findings of the role of growth factors on vasculogenesis and endotheliogenesis, this study was conducted to determine the role of FGF and VEGF in the endothelial behavior of ASCs and contribution of these growth factors to the ability of ASCs to differentiate to endothelial-like cells. This study hypothesized that treatment of cells with FGF or VEGF would stimulate the ASCs to differentiate to endothelial-like cells that are phenotypically and functionally similar to true endothelial cells. Furthermore, the combination of FGF and VEGF (FGF/ VEGF) would have a synergistic increase in the activation of stem cells.
METHODS
Isolation and culture of human ASCs. In accordance with an Investigational Review Board-approved protocol, informed consent was obtained from all patients before collection of adipose samples. Adipose tissue was obtained from the abdomen and breast of patients undergoing cosmetic liposuction and breast reduction. Liposuctioned adipose tissue was washed and incubated in collagenase I solution with bovine serum albumin (1 mg/mL þ 4 mg/mL; Worthington, Lakewood, NJ) for 1 hour at 37 C. Cells were centrifuged at 1500g for 10 minutes and washed with phosphatebuffered solution (PBS). The stromal vascular cells were cultured at 37 C in 5% CO 2 in medium M199 (Mediatech Inc, Manassas, Va) and supplemented with 10% fetal bovine serum (FBS) and antibiotic/antimycotic solution (Gemini Bio-Products, West Sacramento, Calif). Nonadherent cells were removed after 24 hours, and the culture medium was replaced twice weekly. Cells were split 3:1 when w80% confluence was reached.
Cell proliferation and doubling time. Proliferation was assessed by constructing growth curves over an 8-day period. ASCs (n ¼ 6) were plated into 24-well plates at 5 Â 10 3 cells/cm 2 with M199 medium and treated with 10 ng/mL FGF, 50 ng/mL VEGF (Gemini BioProducts), or FGF/VEGF for 8 days with replenishment of medium every 3 to 4 days. At various times, cells were trypsin-released and counted using a Coulter counter (Beckman Coulter Inc, Fullerton, Calif). Doubling time was calculated for the log phase of growth (between days 0 and 8) using the formula doubling time ¼ (t À t 0 ) log2/ (logN À logN 0 ), where t and t 0 are the times at which the cells were counted, and N and N 0 are the cell numbers at times t and t 0 , respectively. Cells cultured in M199 medium were used as the control. All assays were done in triplicate.
MTT assay. MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide) assay was also used to evaluate the effect of FGF and VEGF on ASC proliferation. ASCs (n ¼ 4) were plated at a density of 1 Â 10 4 cells/well in a volume of 1 mL in 24-well plates. At day 2 and day 6, the culture medium was replaced with a medium containing MTT solution (5 mg/mL; SigmaAldrich, St. Louis, Mo) and incubated at 37 C in 5% CO 2 for 4 hours. The wells were decanted, and the purple formazan crystals that formed were dissolved in 200 mL dimethyl sulfoxide (Sigma-Aldrich). The absorbance of the plate was read on a microplate reader at 570 nm. Fresh cells were used as controls. All assays were done in triplicate.
Endothelial differentiation and gene expression. ASCs (n ¼ 4) were cultured in M199 medium supplemented with 10% FBS and FGF (10 ng/mL), VEGF (50 g/mL), or FGF/VEGF for up to 10 days. ASCs cultured in M199 medium and EGM2 medium (Lonza, Basel, Switzerland) were used as controls. The medium was exchanged with fresh medium every 3 days. Total RNA was extracted using TRIzol reagent. (Life Technologies, Grand Island, NY). For each sample, 1 mg of RNA was converted to complementary DNA using reverse transcription via the SuperScript II First-Strand Synthesis System (Life Technologies) according to the manufacturer's protocol.
To detect the specific genes expressed, reverse transcription polymerase chain reaction (PCR) was performed using the following primers: Levels of mRNA were quantified using SYBR Green Real-Time PCR with the 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, Calif). PCR reaction conditions were 95 C for 10 minutes, followed by 40 cycles of 95 C for 15 seconds, and 60 C for 1 minute. The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (5-primers: 5 0 -GGATCTCGCTCCTGGAAGATG-3 0 and 3-primers: 5 0 -GCACCGTCAAGGCTGAGAAC-3 0 ) was amplified in separate tubes to normalize for variance in input RNA. For relative quantification, the efficiency of amplification for each individual primer pair was determined using the complementary DNA target and the 2 ÀDDct method. Matrigel-based capillary-like tube formation assay. After 10 days of culturing in FGF, VEGF, or FGF/VEGF medium, ASCs (n ¼ 4) were plated on Matrigel (BD Biosciences, San Jose, Calif) substrate at a density of 2 Â 10 5 cells/100 mL Matrigel and incubated at 37 C in 5% CO 2 for up to 12 hours. Formation of cord-like structures was visualized by phase-contrast microscopy. ASCs cultured in nondifferentiation M199 medium were used as the control.
Immunofluorescence. ASCs (n ¼ 3) were cultured in FGF or FGF/VEGF medium for 10 days. Untreated cells were used for the control. Cells were fixed for 15 minutes in 4% formaldehyde at room temperature and permeabilized with 0.3% Triton X-100 for 5 minutes. The cells were blocked with 10% goat serum in PBS for 1 hour and incubated with a primary antibody eNOS (BD Transduction, San Jose, Calif) overnight at 4 C. The secondary fluorescent antibody was used for the detection of the positive cells. Nucleus was stained with a 4 0 ,6-diamidino-2-phenylindole containing Vectashield mounting medium (Vector Laboratories Inc, Burlingame, Calif). Images were acquired using a FluoView 1000 confocal immunofluorescent microscope (Olympus, Center Valley, Pa).
Flow cytometry. ASCs (n ¼ 3) were cultured in FGF, VEGF, or FGF/VEGF medium for 2 weeks. Approximately 5 Â 10 5 cells were incubated with fluorescenceconjugated CD31 (fluorescein isothiocyanate-conjugated; BD Biosciences). Isotype antibodies served as controls to exclude nonspecific binding. Quantitative analysis was performed using fluorescence-activated cell sorting caliber flow cytometer (Beckman) and FlowJo software (TreeStar, Ashland, Ore).
Migration assay. ASCs (n ¼ 4) were plated into 12-well plates at 1 Â 10 5 cells per well. ASCs were cultured in FGF, VEGF, or FGF/VEGF for 10 days. ASCs cultured in M199 medium were used as a control. Once the cells reached confluence, a "wound" was made with a tip causing a scratch. and medium with FGF, VEGF or FGF/VEGF was added. Photographs were taken at the start and 24 hours after wound induction. Cell migration was quantified by measuring the shortest distance between scratch edges at 0 and 24 hours after introduction of the scratch in three different fields per scratch. The location of the scratch was in the middle of each well.
Adhesion potential. To identify the ability of the ASCs to attach on the scaffold membrane components in vitro, a small intestinal submucosa (SIS) sheet was provided as a soft tissue graft from Cook Medical (Bloomington, Ind). ASCs (n ¼ 3) were resuspended in M199 medium (10% FBS), with or without FGF, VEGF, or FGF/VEGF, at a density of 2.5 Â 10 6 cells/mL and a 0.4-mL cell suspension (1 Â 10 6 cells), and were seeded onto the SIS sheet (2 cm 2 ). The culture medium was added 4 hours later to the seeded scaffolds and changed every 2 days for a week to allow for cell adhesion. After 1 week, the morphology of the attached ASC s on SIS scaffold was determined by staining the live, seeded cells with CellTracker Green (Molecular Probes/Thermo Fisher, Waltham, Mass) for 20 minutes and visualizing the surface with a laser confocal microscope (Olympus FluoView). The effect of FGF, VEGF, and FGF/VEGF on retention of ASCs after seeding onto the SIS scaffold was quantified indirectly by counting the number of attached cells after cells were released with trypsin.
Inhibition of FGF signaling. ASCs (n ¼ 3) were seeded in 6-well plates at 40% to 60% confluence in M199 medium. Cells were washed 24 hours later with PBS and then incubated in the presence or absence of 100 nmol/L PD173074 (Santa Cruz Biotechnology, Dallas, Tex) for 3 hours. The medium was then changed to M199 media containing FGF (10 ng/mL), with or without 100 nmol/L PD173074. The cells were incubated in this medium for 10 days, with fresh medium replenishment once every 3 days. In each replenishment, the cells were first incubated in M199 medium, with or without 100 nmol/L PD173074, for 3 hours and then maintained in M199/FGF medium, with or without 100 nmol/L of PD173074, for 3 days. RNA isolation, Matrigel-based cord formation, and immunofluorescence studies were repeated in accordance with prior protocols with these "inhibited" cell lines.
Statistical analysis. The data are presented as mean 6 standard error of the mean (SEM). The Student t-test was used to evaluate the significance differences defined as P < .05 between two groups of data in all experiments. Multigroup comparisons were determined by one-way analysis of variance with Bonferroni correction. A value of P < .05 was considered statistically significant. . ASCs cultured in medium with FGF or FGF/ VEGF showed higher proliferation rates than those cultured with M199 medium or VEGF alone. B, MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide) assays record the cell viability of ASCs cultured with FGF, VEGF, and FGF/VEGF at days 2 and 6 (n ¼ 3). C, Doubling times of human ASC generated from growth curves reveal that culture in medium with human FGF or FGF/VEGF resulted in a shorter doubling time (n ¼ 6). Data are shown as the mean 6 standard error of the mean (error bars).
* P < .05.
RESULTS
FGF enhances ASC proliferation and cell viability. ASCs displayed a spindle-shaped, fibroblast-like morphology after culture in medium supplemented with FGF, VEGF, and FGF/VEGF for 1 week. In the FGF and FGF/VEGF groups, the cells reached confluence faster and appeared more compact and spindle shaped compared with the M199 and VEGF-only groups. However, cells in the VEGF group appeared to form clusters, which was not observed in the FGF or M-199 control groups (Fig 1) .
A 3.2-fold higher proliferation rate in ASCs cultured with FGF over those cultured with VEGF, as measured by total cell counts taken several times over an 8-day period (P ¼ .02), was observed. ASCs in the VEGF treatment group did not enhance proliferation rates compared with the control group. However, ASC treatment with VEGF/FGF enhanced the effect observed in ASCs treated with FGF alone (3.5-fold increased, n ¼ 6; P < .05; Fig 2, A) .
The MTT assay revealed that ASCs treated with FGF or FGF/VEGF had higher proliferation rates on day 6 (n ¼ 4; Fig 2, B) . The cumulative population doubling time was shorter for ASCs cultured with FGF compared with VEGF-treated cells (2.8 6 0.33 vs 6.1 6 0.48, n ¼ 4; P < .05; Fig 2, C) .
FGF and VEGF induce ASC differentiation into an endothelial phenotype. Commitment toward an endothelial lineage was further measured by evaluating CD31, vWF, CD144, and eNOS mRNA transcript levels using quantitative PCR. After 10 days of stimulation with FGF or VEGF, ASCs (n ¼ 4) expressed mRNA for endothelial cellspecific markers of CD31, vWF, CD144, and eNOS compared with the control group (Fig 3, A) . Furthermore, ASCs cultured in medium with FGF/VEGF demonstrated increased mRNA levels of CD31 (6.82 6 0.46 vs 3.23 6 1.46; P < .05), vWF (14.03 6 1.26 vs 12.47 61.57), and CD144 (4.66 6 0.56 vs 3.46 6 0.43; P < .05) expression over ASCs differentiated in medium with FGF alone. Interestingly, the CD31, vWF, and CD144 expression was higher in ASCs cultured with FGF and FGF/VEGF compared with ASCs cultured in EGM2 medium. These results indicate that FGF and VEGF are two plausible factors to induce ASC endothelial differentiation.
In addition, immunofluorescence staining assays confirmed protein expression of eNOS in ASCs (n ¼ 3) by FGF and VEGF induction (Fig 3, B) . The expression of CD31 in ASCs (n ¼ 3) was increased by FGF/VEGF induction compared with FGF or VEGF alone (Fig 3,  C) , as seen with flow cytometry assessment. In addition, capillary-like structures formed when plated onto Matrigel after treatment FGF, VEGF, or FGF/VEGF induction (Fig 3, D) .
FGF stimulates functional capabilities of endothelial cells in ASCs. ASC migration properties were also studied with scratch-width assays. Wound healing was quantified by measuring the shortest distance between scratch edges before scratch and at 24 hours after introduction of the The attachment of ASCs in vitro on the SIS scaffold was investigated to further understand the interaction of the FGF and VEGF in ASCs with matrix grafts components and their potential for use in tissue engineering. Laser confocal microscopic images revealed that compared with VEGF, ASCs firmly adhered to the SIS scaffold membrane by FGF and remained 7 days after seeding (Fig 5, A) . In addition, FGF/VEGF showed improvement in ASC attachment (1.3-fold) compared with FGF alone (n ¼ 3; P < .051; Fig 5, B) .
FGF receptor inhibitor blocks ASCs endothelial differentiation. To further confirm the critical role of FGF in ASC endothelial differentiation, ASC differentiation experiments were conducted in the presence or absence of PD173074, a selective inhibitor of FGF receptor. Inhibition of the FGF pathway significantly reduced mRNA expression of CD31 (5.6-fold; P < .05) and eNOS (6.4-fold; P < .05) but not vWF (1.8-fold; Fig 6, A) . The ability of the ASCs to subsequently form capillary-like structures upon plating on Matrigel was inhibited in the presence of PD173074 (Fig 6,  B) . Finally, addition of inhibitor PD173074 to the treatment groups blocked the induction of eNOS expression in ASCs at both mRNA and protein levels (Fig 6, C) .
DISCUSSION
The cornerstone of stem cell-based therapies in the field of vascular medicine is promoting ASCs to endothelial-like derivatives that are phenotypically similar to endothelial cells and functionally able to seed onto tissue-engineered vascular conduits. The ability of this cell line to regenerate from a small quantity of human-derived adipose tissue is beneficial when planning on creating long bypass conduits for patients who have long-segment vascular disease. To evaluate the proliferative capacity of ASCs, growth curve assays and doubling time were evaluated. Those cell lines treated with FGF and FGF/VEGF reached confluence faster than the control group and had statistically significant decreased doubling time. DiMuzio et al 32 discusses a similar phenomenon of ASCs having the ability to potentiate themselves from a small amount of initial adipose tissue. They found that only 50 to 100 g of human-derived adipose tissue would be enough to seed a bypass graft of up to 40 cm Â 6 mm. 32 With a cell line that could replicate rapidly with the introduction of FGF and VEGF medium, studying the cell viability of this new proliferative line of cells was imperative. MTT assays revealed that ASCs treated with FGF had a higher proliferation rate than VEGF, and growth curves constructed during an 8-day study period demonstrated a shorter doubling time, suggesting a benefit to FGF. This is clinically attractive because the large number of cells required for therapy could be achieved more rapidly.
Studies have suggested that cells expressing CD31, vWF, and eNOS could be potential cells used for seeding vascular conduits. 33 In this study, ASCs cultured in medium with FGF/VEGF demonstrated increased levels of endothelial cell markers of CD31, vWF, and CD144 mRNA expression over ASCs cultured with FGF alone or VEGF alone. In addition, flow cytometry results indicated true expression of CD31 in cells treated with FGF and VEGF. Furthermore, compared with EGM2 medium, enhanced results were observed in the FGF and FGF/ VEGF groups. These results suggest that more than one growth factor might be necessary to elicit robust endothelial characteristics of ASCs and that FGF/VEGF may have a costimulatory effect on the endothelial differentiation of ASCs.
The ability of ASCs to express eNOS by FGF was also evaluated. Despite the efforts of several groups, there has been limited to no success in promoting ASCs to express eNOS. 2, 18, 31, 34 Cao et al 2 reported the expression of eNOS mRNA within ASCs after 3 days of culture in medium containing VEGF and FGF; however, protein expression was not reported. Zhang et al 34 showed that supplementing EGM2 with additional VEGF (50 ng/ mL) increased mRNA expression of vWF and eNOS within the ASCs but was significantly less compared with endothelial controls. Similarly, although Ning et al 18 exhibited eNOS immunofluorescent staining in ASCs after culture in medium containing FGF, they did not corroborate these results with transcript level or functional analyses. 18 The ASCs in this study treated with FGF or FGF/VEGF did express low levels of eNOS mRNA. Immunofluorescence was performed to confirm these results. Again, ASCs treated with FGF and FGF/VEGF had evidence of the eNOS immunoreactive protein.
Also important for the potential use of ASCs in regenerative medicine is their ability to obtain the functional capability of endothelial cellsdcord formation, migration, and attachment. A key feature of endothelial cells is the ability to form capillary networks. When plated on Matrigel, endothelial cells form intricate tube-like matrices. 35 These networks mimic the capillary networks necessary for angiogenesis. The ability of cells to migrate to one another is also paramount because this is one of the early stages of angiogenesis. Partridge et al 36 found that overexpression of FGF promotes matrix metalloproteinase-1-mediated endothelial cell migration. 36 That ASCs are able to attach to a biologic matrix is necessary to functionally develop a vascular conduit to allow for bypass grafting. Tissue-engineering techniques have been used to demonstrate the clinical utility of stem cell transplantation in vascular and cartilage reconstruction. 31, 34, 37 SIS has been widely used in the reconstruction of various tissues and organs. 38 With tissue engineering, cell-seeded acellular matrix grafts have achieved prominence as a potential off-the-shelf replacement material. The functionality studies in these experiments focused on the ability of treated stem cells to form cord-like structures on Matrigel, migrate toward one another, and adhere to a biologically derived scaffold.
With the promising results of FGF on differentiation, proliferation, and functional capabilities of ASCs, the FGF signaling pathway in the observed endothelial differentiation of ASCs was investigated. In this study, ASCs inoculated with the FGF receptor inhibitor PD173074 had a significant reduction in endothelial markers, were unable to form precapillary networks, and did not express eNOS at the message or protein levels. These results further indicate that FGF is a critical growth factor involved with the promotion of ASCs to an endothelial-like phenotype consistent with the results reported by Ning et al. 18 
CONCLUSIONS
FGF and VEGF are ASC promoters for endothelial differentiation. These differentiated cells exhibited improved proliferation, migration, and attachment. FGF and VEGF have a costimulatory effect on ASC endotheliogenesis. These results suggest that ASCs enhanced with FGF in the presence of VEGF may potentially be used for tissue engineering and cell-based therapies in patients with critical limb ischemia. 
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